Allopregnanolone (ALLO) and tetrahydrodeoxycorticosterone (THDOC) are potent positive allosteric modulators of GABA action at GABAA receptors. ALLO and THDOC are synthesized in the brain from progesterone or deoxycorticosterone, respectively, by the sequential action of two enzymes: 5␣-reductase (5␣-R) type I and 3␣-hydroxysteroid dehydrogenase (3␣-HSD). This study evaluates 5␣-R type I and 3␣-HSD mRNA expression level in mouse brain by using in situ hybridization combined with glutamic acid decarboxylase 67͞65, vesicular glutamate transporter 2, glial fibrillary acidic protein, and S100␤ immunohistochemistry. We demonstrate that 5␣-R type I and 3␣-HSD colocalize in cortical, hippocampal, and olfactory bulb glutamatergic principal neurons and in some output neurons of the amygdala and thalamus. Neither 5␣-R type I nor 3␣-HSD mRNAs are expressed in S100␤-or glial fibrillary acidic protein-positive glial cells. Using glutamic acid decarboxylase 67͞65 antibodies to mark GABAergic neurons, we failed to detect 5␣-R type I and 3␣-HSD in cortical and hippocampal GABAergic interneurons. However, 5␣-R type I and 3␣-HSD are significantly expressed in principal GABAergic output neurons, such as striatal medium spiny, reticular thalamic nucleus, and cerebellar Purkinje neurons. A similar distribution and cellular location of neurosteroidogenic enzymes was observed in rat brain. Taken together, these data suggest that ALLO and THDOC, which can be synthesized in principal output neurons, modulate GABA action at GABAA receptors, either with an autocrine or a paracrine mechanism or by reaching GABAA receptor intracellular sites through lateral membrane diffusion.
T
he neurosteroids 3␣-hydroxy-5␣-pregnan-20-one [allopregnanolone (ALLO)] and 3␣,21-dihydroxy-5␣-pregnan-20-one [tetrahydrodeoxycorticosterone (THDOC)] are potent positive allosteric modulators of GABA action at GABA A receptors (1) (2) (3) (4) (5) (6) . These neurosteroids can be synthesized in the brain from progesterone (7) or deoxycorticosterone (8, 9) , respectively, by the sequential action of two enzymes, 5␣-reductase (5␣-R) type I and 3␣-hydroxysteroid dehydrogenase (3␣-HSD) (10) .
Two types (I and II) of 5␣-Rs, which convert progesterone into 5␣-dihydroprogesterone (5␣-DHP) or convert deoxycorticosterone into 5␣-dihydrodeoxycorticosterone (5␣-DHDOC), have been identified in tissues of rodents and humans (11) . Whereas 5␣-R type I and II are abundantly expressed in several peripheral tissues, 5␣-R type I is the most abundant 5␣-R molecular form detected in the adult brains of rats, mice, and humans (11) (12) (13) (14) (15) (16) (17) . The human brain expresses four types of 3␣-HSD, which, under different optimal conditions, either catalyze the reduction of 5␣-DHP into ALLO or reverse this reaction (18) . So far, only one 3␣-HSD isoform has been identified in the rat or mouse brain (19) (20) (21) (22) . The mRNA sequences of 5␣-R type I (Ϸ88%) and 3␣-HSD (Ϸ89%) are highly homologous in mouse (5␣-R type I GeneBank accession number (GBAN) NM175283.3; 3␣-HSD, GBAN AY730283.1) and rats (5␣-R type I, GBAN NM017070.3; 3␣-HSD, GBAN NM138547.1).
In various mouse and rat brain regions, the rank order of 5␣-R type I and 3␣-HSD expression matches the nonuniform distribution of ALLO and 5␣-DHP (7, 14) . A down-regulation of brain 5␣-DHP and ALLO can be induced by environmental factors (i.e., social isolation) (23) (24) (25) (26) and may be mediated by a decrease of brain 5␣-R type I expression (14) . Taken together, this information suggests that 5␣-R type I and 3␣-HSD may act in concert to control ALLO or THDOC and 5␣-DHP or 5␣-DHDOC biosynthesis.
Neuronal cultures from neonatal or embryonic rats synthesize ALLO and express 5␣-R type I (27) (28) (29) . However, in the adult rat brain, 5␣-R type I immunoreactivity is expressed primarily by glial cells that also express S100␤ (30, 31) . Hence, it is not clear whether 5␣-R type I is selectively expressed in the neurons of the adult rodent brain and whether it coexists with 3␣-HSD.
Because GABA A receptors are expressed in neuronal populations of several brain regions, it is important to establish whether ALLO, which positively modulates GABAergic signal transduction, is released from GABAergic axon terminals directly on GABA A receptors or if it reaches GABA A receptors by diffusion from contiguous synapses, perhaps via a local paracrine mechanism. This article deals with our attempts to clarify these issues by using mouse brain sections and in situ histochemistry technologies to compare the subcellular expression of 5␣-R type I and 3␣-HSD in various brain regions. We also have combined in situ antisense hybridization and immunohistochemistry labeling with specific markers to verify the brain-region distribution of neurons coexpressing 5␣-R type I and 3␣-HSD with confocal fluorescence microscopy.
Results
Cerebral Cortex. 5␣-R type I (Fig. 1a) and 3␣-HSD (Fig. 1b) mRNAs are expressed in somatosensory ( Fig. 1aA and bA) and piriform ( Fig. 1aF and bF) cortices. In the somatosensory cortex, 5␣-R type I and 3␣-HSD mRNAs are primarily expressed in layer II, III, and V pyramidal neurons. The expression of these transcripts is below detection limits in layer I neurons, which are mostly GABAergic (32, 33) . The hybridization signals for 5␣-R type I and 3␣-HSD are mostly similar, but there are some differences. For example, 5␣-R type I mRNA expression is primarily cytosolic (Fig. 1 aA) , whereas 3␣-HSD mRNA expression appears to be cytosolic and nuclear (Fig. 1bA) .
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mRNA and 5␣-R type I protein show that, very frequently (Ͼ95%), both enzymes are coexpressed in the same neurons. Fig. 2B shows that vesicular glutamate transporter (VGLUT)1 mRNA, a glutamatergic neuronal marker, and 5␣-R type I protein colocalize. In contrast, we could not detect a colocalization of 5␣-R type I or 3␣-HSD with glutamic acid decarboxylase (GAD)67͞65 (Fig. 2D) , a marker for GABAergic neurons. Finally, 5␣-R type I mRNA fails to colocalize with S100␤, a specific glial cell marker (Table 1) .
Hippocampus.
The detection signals for 5␣-R type I and 3␣-HSD mRNAs are reported in Fig. 1 aB and bB, respectively. The hybridization signal of both expressed transcripts in CA1 and CA2 is very intense, but, in CA3, the signal is faint. The cells of dentate gyrus and hilus also show a less-intense staining than that detected in CA1 and CA2, especially in the case of 5␣-R type I (Fig. 1 aB) . The stratum oriens, stratum radiatum, and layer lacunosum moleculare, and the molecular layers of the dentate gyrus show faint hybridization signal. However, a few cells are labeled for 5␣-R type I mRNA in the stratum radiatum and, very likely, these are interneurons. A coexistence of 5␣-R type I or 3␣-HSD mRNAs with GAD67͞65 immunoreactivity was not detected (Table 1 ). In the hippocampus, as in the cortex, the 5␣-R type I signal fails to colocalize with S100␤ (Fig. 3C) . As in the cortex, in CA1 pyramidal neurons, the 5␣-R type I in situ hybridization signal consistently colocalizes with the VGLUT2 immunostaining (Fig. 3A) .
The VGLUT2 antibodies predominantly label glutamatergic neuron axon terminals (34) . However, under the conditions of double in situ hybridization and immunohistochemistry shown in Fig. 3A , the cell bodies are also labeled. This labeling is eliminated when the VGLUT2 antiserum is preabsorbed with the immunizing peptide (Fig. 3B) .
Olfactory Bulb. The olfactory bulb is characterized by the expression of intense 5␣-R type I (Fig. 1 aC) and 3␣-HSD (Fig. 1bC) hybridization signals, primarily expressed in the mitral and periglomerular cells. The granule GABAergic neurons, express faint staining for both 5␣-R type I and 3␣-HSD (Fig. 4A) . In the mitral cell layer, 5␣-R type I mRNA colocalizes with VGLUT1 mRNA (data not shown) or with VGLUT2 proteins (Fig. 4A) . However, we failed to observe the colocalization of 5␣-R type I mRNA with glial fibrillary acidic protein, a specific glial cell marker (Table 1) .
Striatum. The striatum includes numerous neurons that express strong 5␣-R type I (Fig. 1aE ) and 3␣-HSD (Fig. 1bE) staining. Confocal fluorescence images show that 5␣-R type I mRNA colocalizes with GAD67͞65 in striatal neurons (Fig. 4B ).
Thalamus. Sparse 5␣-R type I (Fig. 1 aG) and 3␣-HSD mRNA ( Fig. 1 bG) positive neurons are expressed in various thalamic nuclei. An intense hybridization signal is detected in neurons of the reticular thalamic nucleus (RtN), where 5␣-R type I is colocalized with GAD67͞65 ( Fig. 4C ). In contrast, in the ventromedial thalamic nucleus, 5␣-R type I colocalizes with VGLUT1 mRNA and VGLUT2 proteins (Table 1) .
Amygdala. The central and basolateral amygdaloid nuclei are characterized by sparse neurons exhibiting a faint staining for either 5␣-R type I ( Fig. 1 aF) or 3␣-HSD mRNAs ( Fig. 1 bF) . Strong staining is expressed in the basolateral anterior amygdaloid nucleus (BLA), whereas, in the central amygdaloid nucleus, staining is weak. The somata of glutamatergic principal neuron expressed in the BLA show a colocalization of 5␣-R type I mRNA with VGLUT2 (Table 1) .
Cerebellum. The staining of 5␣-R type I and 3␣-HSD mRNA is selectively localized in the somata of Purkinje neurons ( Fig. 1 aD  and bD) . A fainter staining is also present in the granule cell layer but virtually absent in the molecular layer. As expected, 5␣-R type I mRNA is colocalized with GAD67͞65 proteins in Purkinje cells (Table 1) .
Overview of 5␣-R Type I and 3␣-HSD mRNA Expression in the Mouse
Brain. Table 1 shows that, in the mouse brain, 5␣-R type I and 3␣-HSD are expressed in principal output neurons, for in- stance, by the glutamatergic principal output neurons in the cortex, hippocampus, olfactory bulb, thalamus, and amygdala and also by GABAergic principal output neurons from the striatum, RtN, and cerebellum. However, 5␣-R type I and 3␣-HSD have not been detected in cortical and hippocampal GABAergic interneurons. The expression of 5␣-R type I and 3␣-HSD could not be detected in S100␤-or glial fibrillary acidic protein-positive cells in various brain areas, including the corpus callosum.
Discussion
Brain Regional and Cellular Distribution of Enzymes Regulating Neurosteroid Biosynthesis. The expression of 5␣-R type I and 3␣-HSD transcripts was greater in the mitral cell layer of the olfactory bulb than in layer II, III, or V of the neocortex or CA1-3 and dentate gyrus of the hippocampus. In these structures, the transcript expression was stronger than in the striatum, thalamus, amygdala, or cerebellum. This brain-region distribution of 5␣-R type I and 3␣-HSD is consistent with that of the distribution of their respective mRNAs quantified with RT-PCR in homogenates of various mouse brain regions (14) .
The identification of cell types expressing 5␣-R type I and 3␣-HSD was carried out by using specific neuronal or glial markers, such as S100␤ and glial fibrillary acidic protein (for glial cells), VGLUT1 and VGLUT2 (for glutamatergic neurons), and GAD67͞65 (for GABAergic neurons).
Regardless of the brain region studied, 5␣-R type I and 3␣-HSD appear to colocalize in the same neuronal population. A systematic cellular mapping of the transcripts for these two specific neurosteroidogenic enzymes indicates that 5␣-R type I and 3␣-HSD expression occurs in neurons but not in glial cells. In neurons, this expression is independent of the chemical structure of the neurotransmitter phenotype (glutamatergic or GABAergic). The neurosteroidogenic enzymes are highly expressed in ''principal'' output neurons (i.e., glutamatergic pyramidal, GABAergic reticulothalamic, striatal, and Purkinje neurons) and are virtually absent in GABAergic interneurons expressed in both the telencephalon or hippocampus ( Table 1 ). The only interneurons that express weak staining for both 5␣-R type I and 3␣-HSD are the GABAergic granule cells of the olfactory bulb and the glutamatergic granular neurons of the cerebellum ( Table 1) .
The evidence that the 5␣-R type I mRNA and protein and the 3␣-HSD mRNA are highly expressed in neurons of the adult mouse brain confirms the Melcangi et al. (27, 28) finding on the expression of 5␣-R type I activity in primary cultures of neurons obtained from various brain regions of rat embryos. Our studies, however, differ from the preceding immunohistochemical studies conducted with 5␣-R type I antibodies (30, 31, 35) in rat brains. In fact, using a specific 5␣-R type I antibody (see Fig. 2C for specificity) we could not confirm, in mouse brain, the studies in rats (30, 31, 35) showing that 5␣-R type I immunoreactivity is abundantly expressed in glial cells. In preliminary experiments, we observed that, in the rat brain, the distribution and cellular The degree of immunostaining intensity is indicated by (ϩϩϩ), (ϩϩ), (ϩ͞Ϫ), and (Ϫ). *The neurotransmitters expressed by these cells were not characterized.
location of 5␣-R type I mRNA is virtually identical to that of mouse. This apparent discrepancy in 5␣-R type I cellular distribution patterns between our in situ hybridization and the above-mentioned immunohistochemical studies (30, 31, 35) may be resolved by considering the differences in mRNA and protein expression: the former is highly localized in cell bodies, and the latter is expressed in axon terminals and dendrites where only a weak staining could be detected.
Significance of 5␣-R Type I and 3␣-HSD Expression Heterogeneity in Specific Neuronal
Populations. GABAA receptor modulation by neurosteroids expressed in GABAergic neurons. Belelli and Lambert (5) have hypothesized that neurosteroids (i.e., ALLO or THDOC) secreted from axon terminals of GABAergic neurons will impinge on GABA A receptors and modulate GABA action at postsynaptically or extrasynaptically expressed GABA A receptors located on dendrites or cell bodies of glutamatergic or GABAergic neurons. The GABAergic neurons of the RtN express high levels of 5␣-R type I and 3␣-HSD, and their nerve endings may secrete neurosteroids and release GABA in the proximity of GABA A receptors located postsynaptically on somata of glutamatergic thalamocortical output neurons located in the mediodorsal thalamus (36) . Similar properties may also apply to medium spiny GABAergic neurons of the caudate or putamen. These neurons express 5␣-R type I and 3␣-HSD and could potentially release GABA and neurosteroids on GABA A receptors expressed in cell bodies or dendrites of nigrostriatal dopaminergic neurons in the substantia nigra (37) or on GABA A receptors located on glutamatergic neurons somata projecting to the thalamus. This finding suggests that, in the basal ganglia, neurosteroids are operative in the modulation of circuits regulating sensory, motor, cognitive, and motivational functions. Finally, a positive allosteric modulatory action of neurosteroids very likely also applies to the Purkinje cells that modulate GABA A receptors located postsynaptically on the cell bodies or the dendrites of deep cerebellar nuclei (dentate, emboliform, globose, and fastigial) neurons.
GABAA receptor modulation by neurosteroids expressed in glutamatergic
neurons. The above-described classic circuitry scheme may not explain the positive allosteric modulatory action of ALLO or THDOC on GABA A receptors located in the cell bodies or dendritic membranes of pyramidal neurons in the cortex and hippocampus or on mitral cells in the olfactory bulb. This supposition is inferred from the notion (Figs. 2, 3 , and 4 A and Table 1 ) that 5␣-R type I and 3␣-HSD are not expressed in GABAergic interneurons but, rather, are expressed in the same glutamatergic principal neurons that also express GABA A receptors.
These data may support the view that neurosteroids synthesized in principal corticolimbic glutamatergic output neurons [including axon terminals of neighboring pyramidal neurons or thalamocortical (36) , or amygdalocortical glutamatergic neurons (38) ] probably act in a paracrine fashion at GABA A receptors located on cell bodies or dendrites of distal cortical pyramidal neurons. We can also propose that neurosteroids act at GABA A receptors located on dendrites or cell bodies of cortical pyramidal neurons after being secreted in an autocrine fashion from dendrites or cell bodies of the same neurons.
Furthermore, one could propose that ALLO or THDOC, synthesized in either cortical and hippocampal pyramidal neurons or in mitral cells might not be released but may access GABA A receptors located on the cell bodies or dendritic membranes of glutamatergic neurons by acting at the intracellular sites of the GABA A receptors by lateral diffusion into the plasma membrane without being secreted into the extracellular milieu (39) .
Neurosteroid effects distinct from an allosteric direct action on GABAA receptors. In independent studies, it was found that, in addition to 5␣-R type I and 3␣-HSD, cortical and hippocampal neurons express 20␣-HSD, the enzyme that converts progesterone into the inactive 20␣-hydroxyprogesterone or converts ALLO into 20␣-hydroxyallopregnanolone (40) . Cortical and hippocampal neurons also express 3␤-HSD, the enzyme that converts pregnanolone into progesterone (41) . Thus, glutamatergic cortical and hippocampal neurons and, also, very likely, the olfactory mitral neurons, may synthesize both progesterone and 5␣-DHP, which may be involved in the regulation of intracellular progesterone-receptor function.
In this context, it is noteworthy to mention that neurosteroids have been reported to (i) influence prefrontal cortex structure and thalamocortical connectivity (42), (ii) increase cerebellar granule-cell neurogenesis (43), (iii) increase the proliferation of neuroprogenitor cells expressed in the rat hippocampus (44) , and (iv) increase the proliferation of human embryonic neural stem cells expressed in the cerebral cortex (44) . It is probable that a receptor mechanism different from a direct modulation of GABA A receptor signal transduction may be operative in these actions. We can speculate that the microtubular-associated protein 2 (MAP2) is a possible putative intracellular receptor for neurosteroids (i.e., ALLO) (45) .
Conclusion
A decrease of brain neurosteroid availability has been associated with psychiatric conditions, including anxiety, aggression, premenstrual dysphoria, and cognitive and mood disorders. Antidepressants (fluoxetine and other selective serotonin-reuptake inhibitors, ''SSRIs'') and antipsychotics (clozapine) may exert their beneficial effects, at least in part, by increasing the brain levels of neurosteroids (26, (46) (47) (48) .
Although the neurosteroids that act as positive allosteric modulators of GABA action at GABA A receptors were initially considered endocrine messengers that are indiscriminately synthesized and secreted from glial cells in all brain regions, the present histochemical data suggest that there is a cellular and molecular basis to imply that neurosteroids are synthesized in neurons and act locally at GABA A receptors expressed on specific corticolimbic circuitries. Understanding the contribution of local brain neurosteroid biosynthesis to the pathogenesis of neurological and psychiatric disorders may become a stimulus to develop new psychoactive drugs that act selectively by normalizing neurosteroid action on GABAergic neurotransmission. (49) were incubated for 72 h at 42°C with a mixture of 50 pmol͞ml of three antisense oligonucleotide probes: R1 (nt 910-933), R2 (nt 989-1,012), and R3 (nt 1180-1203) (GBAN NM175283). To visualize 3␣-HSD mRNA, adjacent sections were incubated with two antisense oligonucleotide probes, H1 (nt 526-549) and H2 (nt 804-827) (GBAN AY730283.1). To visualize VGLUT1 mRNA, we used a hybridization technique with antisense oligonucleotide probes complementary to bases 626-649 (V1) and 1499-1522 (V2) of the mouse VGLUT1 cDNA (GBAN NM182993). The oligonucleotide 3Ј terminals were labeled with digoxigenin by using the Oligonucleotide Digoxigenin Tailing kit (Roche Diagnostics, Indianapolis, IN). The in situ hybridization protocol followed a variation of the procedure described by Rodriguez et al. (32) for the avidin-biotinperoxidase complex (ABC; Vector Laboratories, Burlingame, CA) method and by Pesold et al. (50, 51) and Veldic et al. (52) for confocal immunofluorescence. Antisense probes: specificity tests. The antisense probe sequences did not match any other known mRNA sequences, as determined by multiple genome-wide BLAST comparisons. However, because genomic sequences that have not been reported as part of the intron͞exon structures of transcribed genes can be transcribed (53), we performed separate in situ hybridization studies with the three 5␣-R type I antisense probes, the two 3␣-HSD antisense probes, and the two VGLUT1 antisense probes to establish specificity. In coronal prefrontal cortex slices, the distribution of neurons stained with the 5␣-R type 1 probe R1 is virtually identical to the distribution of neurons stained with probes R2 and R3. The distribution of neurons stained with the 3␣-HSD probe H1 is also virtually identical to the distribution of neurons detected with H2. The same virtually identical distribution was also found with the VGLUT1 probes V1 and V2. Oligoprobe specificity was tested by using digoxigenin-labeled scrambler oligonucleotides for 5␣-R type I, 3␣-HSD, and VGLUT1. As expected, specific neuronal staining was not detected. Double in Situ Hybridization and Immunohistochemistry. Double in situ hybridization and immunohistochemistry were performed by following a variation of the procedure described by Pesold et al. (50, 51) and Veldic et al. (52) . After the in situ hybridization procedure was terminated, the following antibodies were used: (i) rabbit anti-GAD67͞65 (diluted 1:2,000; Chemicon, Temecula, CA), (ii) rabbit anti-VGLUT2 (diluted 1:500; Synaptic Systems, Gottingen, Germany), (iii) rabbit anti-GFAP (diluted 1:250; Chemicon), (iv) rabbit anti-S-100␤ (diluted 1:5,000; Swant, Bellinzona, Switzerland), and (iv) rabbit anti-rat 5␣-R type I (diluted 1:100; Acris Antibodies, Hiddenhausen, Germany).
Materials and Methods
After the double in situ hybridization and immunohistochemistry procedures, the slices were incubated with Cy5-labeled goat anti-rabbit IgG (diluted 1:1,000; Amersham Biosciences, Piscataway, NJ) or Cy5-labeled goat anti-guinea pig IgG (diluted 1:1,000; Abcam, Cambridge, MA) to produce red fluorescent staining or Cy2-labeled streptavidin (diluted 1:1,000; Amersham Biosciences) to produce green fluorescent staining, as indicated in the figure legends. The number of cells in which green and red fluorescence colocalize compared with the number of cells that express only green or only red fluorescence was quantified with confocal microscopy (Leica, Bannockburn, IL) at a magnification of ϫ40 in a counting box of 100 ϫ 100 ϫ 20 m.
Western Blot Analysis to Assess 5␣-R Type I and VGLUT2 Antibody Specificity. Mouse brain extracts (10 mg per 200 l of SDS loading buffer) were electrophorized on 10-20% SDS͞PAGE gel and blotted onto a nitrocellulose membrane (Amersham Biosciences). For the study of 5␣-R type I antiserum specificity, the membranes were incubated with either anti-5␣-R type I (diluted 1:2,500; Acris Antibodies) or anti-5␣-R type I (diluted 1:2,500) preabsorbed for 12 h at 4°C with a 1 mM solution of the immunizing peptide (V-V-F-A-L-F-T-L-S-T-L-T-R-A-K-Q-H-H-Q-W-Y) in 0.005 M NaPHO 4 buffer (pH 7.2), 0.2 M NaCl, and 5% BSA. Two immunoreactive bands, one of Ϸ45 kDa and one of Ϸ29 kDa, are recognized by the nonpreabsorbed antiserum (Fig. 2C1) . The immunoreactive bands disappear when the preabsorbed antiserum is used (Fig. 2C2) . The size of 5␣-R type I in mice is Ϸ29 kDa, according to the GenBank accession no. AAH94503; however, as indicated by Russell and Wilson (11) , the hydrophobic amino acid content of 5␣-R type I (Ϸ37%) may explain the aberrant electrophoretic mobilities in SDD͞PAGE that have been reported for the 5␣-R isoenzymes. The preabsorbed antiserum failed to immunoreact with mouse brain slices.
The membranes were also incubated with anti-VGLUT2 antiserum (diluted 1:4,000; Synaptic Systems) or anti-VGLUT2 anti-
